

To NZX Limited

And Rua Bioscience Limited

Date this disclosure made: 22 December 2022

Date on which substantial holding began: 20 December 2022

Substantial security holder(s) giving disclosure

Name(s): Michael John Wilding

Summary of substantial holding to which disclosure relates

Class of listed voting securities: Ordinary Shares

Summary for Michael John Wilding

For this disclosure,—

(a) total number held in class: 8,509,556

(b) total in class: 158,019,267

(c) total percentage held in class: 5.385%

Details of relevant interests

Details for Michael John Wilding

Nature of relevant interest(s): Registered holder and beneficial owner of financial products

For that relevant interest,—

(a) number held in class: 4,254,778

(b) percentage held in class: 2.693%

(c) current registered holder(s) of securities: Michael John Wilding

(d) registered holder(s) of securities once converted: Michael John Wilding

Details of transactions and events giving rise to person beginning to have substantial holding

Details of the transactions or other events requiring disclosure: Conversion of 4,254,778 non voting performance shares to ordinary shares on satisfaction of Milestone One as consideration for the acquisition by Rua Bioscience Limited of Zalm Therapeutics Limited

Additional information

Address of substantial product holder: 283 Waimarama Road, Rd 12, Havelock North, 4294

Contact details: Jonathan Norman, jon@slw.co.nz, (06)651 1150

Declaration

I, Jonathan Oswald Norman, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.